New Institutional shareholder

January 21 | 2022

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announces today that Gainbridge Novus Nordic has acquired 80,000 shares from Jürgen Kupper, Managing Director at 2cureX GmbH.

Gainbridge Novus Nordic, a Swedish fund managed by Gainbridge Capital, has acquired 80,000 shares from Jürgen Kupper, Managing Director at 2cureX GmbH.

The transaction has taken place as a block trade with no impact on the share price in the market. Jürgen Kupper had previously acquired 169,600 shares through a warrant program. The proceeds from the transaction will cover costs associated with his initial investment as well as taxes related to the warrants. After the transaction Jürgen Kupper will still hold a significant position in 2cureX.

Becoming part of the forward journey

Cedric Jirsell, Portfolio Manager for Gainbridge Novus Nordic comments: "we find 2cureX a very interesting company at an interesting stage following its first commercial order last month. During 2021 they laid the foundation for an accelerated growth during 2022 and 2023 as already established partners across Europe start delivering orders. We are excited about this opportunity to get on board as an investor and become part of the forward journey."

A recognized and respected investor

Fernando Andreu, CEO of 2cureX comments: "we are delighted to welcome Gainbridge Novus Nordic on board. It’s a recognized and respected mid-term investor with a focus on innovation and growth and we see their interest in 2cureX as a recognition of the potential of the company. We are looking forward to further strengthening our investor base by attracting more Nordic and international institutional investors like them."